HIGHRegulatoryTier 1
Unique Pharmaceutical Laboratories (A Div. of J. B. Chemicals & Pharmaceuticals Ltd.) Issues Voluntary Nationwide Recall of Cetirizine Hydrochloride Tablets USP 5 mg Due to Potential Cross Contamination with Ranitidine
Summary & scoring by The Bell Brief (Dr. Jennifer Bell) using the Drill-Down Protocol (Drill-Down Score) — not the original publisher.
Why it matters for dental
Dental practices that dispense or recommend OTC cetirizine tablets (e.g., allergy or sinus adjuncts) must immediately quarantine the affected lots to avoid providing patients with tablets potentially cross-contaminated with ranitidine, whose NDMA impurity poses regulatory and liability risks for the prescribing dentist.
Key points
- Four lots of Cetirizine Hydrochloride Tablets USP 5 mg manufactured by Unique Pharmaceutical Laboratories (India) are under voluntary consumer-level recall as of July 18, 2026.
- The recall cites cross-contamination with ranitidine, a compound whose NDMA impurity has previously triggered FDA alerts; dentists should verify lot numbers on office inventory and patient samples.
- Dentists and DSO procurement teams should contact their wholesalers/distributors to confirm whether any stock on hand matches the recalled lots and arrange returns or replacements.
- Front-desk and clinical staff should be instructed not to dispense or recommend the product until clearance, updating allergy-management protocols accordingly.
Who should care
OwnerDSOStaff
Read the original on FDA Recalls
Full reporting and any paywall content live on fda.gov. We summarize and score; we do not republish.